Protective effect of silymarin against cisplatin-induced ototoxicity

International Journal of Pediatric Otorhinolaryngology

Volumn 78, Issue 3, 2014, Pages 474-478

  Cho, Sung Il ^a   Lee, Ji Eun ^a   Do, Nam Yong ^a  

^a Chosun University   (South Korea)

Author keywords

Apoptosis; Cisplatin; Ototoxicity; Silymarin

Indexed keywords

APOPTOSIS; CISPLATIN; OTOTOXICITY; SILYMARIN;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CISPLATIN; HAIR CELLS, AUDITORY; HEARING LOSS; MICE; MICE, TRANSGENIC; ORGAN OF CORTI; REACTIVE OXYGEN SPECIES; SENSITIVITY AND SPECIFICITY; SILYMARIN;

EID: 84893768376     PISSN: 01655876     EISSN: 18728464     Source Type: Journal    
DOI: 10.1016/j.ijporl.2013.12.024     Document Type: Article

References (34)

1. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
2. Hartmann J.T., Lipp H.P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4:889-901.
3. Dehne N., Lautemann J., Petrat F., Rauen U., de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol. Appl. Pharmacol. 2001, 174:27-34.
4. Pigeolet E., Corbisier P., Houbion A., Lambert D., Michiels C., Raes M., et al. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech. Ageing Dev. 1990, 51:283-297.
5. Clerici W.J., DiMartino D.L., Prasad M.R. Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear. Res. 1995, 84:30-40.
6. Rybak L.P., Whitworth C.A. Ototoxicity: therapeutic opportunities. Drug Discov. Today 2005, 10:1313-1321.
7. Kren V., Walterová D. Silybin and silymarin - new effects and applications. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2005, 149:29-41.
8. Abenavoli L., Capasso R., Milic N., Capasso F. Milk thistle in liver diseases: past, present, future. Phytother. Res. 2010, 24:1423-1432.
9. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001, 61:2035-2063.
10. Vaid M., Katiyar S.K. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.). Int. J. Oncol. 2010, 36:1053-1060. (Review).
11. Hogan F.S., Krishnegowda N.K., Mikhailova M., Kahlenberg M.S. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J. Surg. Res. 2007, 143:58-65.
12. Cheung C.W., Gibbons N., Johnson D.W., Nicol D.L. Silibinin - a promising new treatment for cancer. Anticancer Agents Med. Chem. 2010, 10:186-195.
13. Ramasamy K., Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008, 269:352-362.
14. Kalinec G.M., Webster P., Lim D.J., Kalinec F. A cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol. Neurootol. 2003, 8:177-189.
15. Im G.J., Chang J.W., Choi J., Chae S.W., Ko E.J., Jung H.H. Protective effect of Korean red ginseng extract on cisplatin ototoxicity in HEI-OC1 auditory cells. Phytother. Res. 2010, 24:614-621.
16. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
17. Langer T., Am Zehnhoff-Dinnesen A., Radtke S., Meitert J., Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol. Sci. 2013, 34:458-469.
18. Casares C., Ramírez-Camacho R., Trinidad A., Roldán A., Jorge E., García-Berrocal J.R. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur. Arch. Otorhinolaryngol. 2012, 269:2455-2459.
19. Lee J.E., Nakagawa T., Kim T.S., Endo T., Shiga A., Iguchi F., et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Oto-Laryngol. 2004, 124:1131-1135.
20. Mansour H.H., Hafez H.F., Fahmy N.M. Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. J. Biochem. Mol. Biol. 2006, 39:656-661.
21. Zi X., Feyes D.K., Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 1998, 4:1055-1064.
22. Sharma G., Singh R.P., Chan D.C., Agarwal R. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res. 2003, 23:2649-2655.
23. Huang Q., Wu L.J., Tashiro S., Onodera S., Li L.H., Ikejima T. Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. J. Asian Nat. Prod. Res. 2005, 7:701-709.
24. Deep G., Singh R.P., Agarwal C., Kroll D.J., Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006, 25:1053-1069.
25. Zhong X., Zhu Y., Lu Q., Zhang J., Ge Z., Zheng S. Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicology 2006, 227:211-216.
26. Mira L., Silva M., Manso C.F. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem. Pharmacol. 1994, 48:753-759.
27. Muriel P., Garciapiña T., Perez-Alvarez V., Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol. 1992, 12:439-442.
28. Karimi G., Vahabzadeh M., Lari P., Rashedinia M., Moshiri M. Silymarin, a promising pharmacological agent for treatment of diseases. Iran J. Basic Med. Sci. 2011, 14:308-317.
29. Huang T., Cheng A.G., Stupak H., Liu W., Kim A., Staecker H., et al. Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int. J. Dev. Neurosci. 2000, 18:259-270.
30. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371:346-347.
31. Watanabe K., Inai S., Jinnouchi K., Baba S., Yagi T. Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs. Auris Nasus Larynx 2003, 30:219-225.
32. Decker P., Muller S. Modulating poly(ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotechnol. 2002, 3:275-283.
33. Ormerod M.G. The study of apoptotic cells by flow cytometry. Leukemia 1998, 12:1013-1025.
34. Vermes I., Haanen C., Reutelingsperger C. Flow cytometry of apoptotic cell death. J. Immunol. Methods 2000, 243:167-190.